Identifiers | |
---|---|
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C55H74IN3O21S4 | |
Molar mass | 1368.34 g·mol−1 |
Hazards | |
GHS labelling: | |
Danger | |
H302, H341, H361, H372 | |
P201, P202, P260, P264, P270, P281, P301+P312, P308+P313, P314, P330, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
The calicheamicins are a class of enediyne antitumor antibiotics derived from the bacterium Micromonospora echinospora,[1] with calicheamicin γ1 being the most notable.[2] It was isolated originally in the mid-1980s from the chalky soil, or "caliche pits", located in Kerrville, Texas. The sample was collected by a scientist working for Lederle Labs.[3] It is extremely toxic to all cells and, in 2000, a CD33 antigen-targeted immunoconjugate N-acetyl dimethyl hydrazide calicheamicin was developed and marketed as targeted therapy against the non-solid tumor cancer acute myeloid leukemia (AML).[4] A second calicheamicin-linked monoclonal antibody, inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration on August 17, 2017, for use in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.[5] Calicheamicin γ1 and the related enediyne esperamicin are the two of the most potent antitumor agents known.[6]